SPDR S&P Biotech ETF (XBI), issued by State Street, reported 152 long positions and $7.4B in net assets in its Mar 2026 N-PORT filing. The ten largest positions account for 20.43% of net assets.
Reporting period: 31 Mar 2026 · 8 filings on file · N-PORT is filed monthly and published quarterly, roughly 60 days in arrears
Net assets
$7.4B
As of Mar 2026
Positions
152
Long positions in the filing
Top 10 weight
20.43%
Top 25: 38.22%
Effective holdings
63
Moderately concentrated
Cash
0.00%
Share of net assets
Securities on loan
18.5605%
112 positions on loan
Sector exposure
4 sectors · Mar 2026
Health Care82.94%
Unclassified9.43%
Funds7.47%
Financials0.16%
Ten largest holdings
Top 10 of 158 positions · Mar 2026
Ten largest holdings reported by XBI as of 31 Mar 2026
#
Security
CUSIP
Value
% of net assets
1
STATE ST INST US GOV MM-PREM
857492706
$595.5M
8.01%
2
APELLIS PHARMACEUTICALS INC
03753U106
$136.4M
1.83%
3
ALKERMES PLC
000000000
$107.9M
1.45%
4
MADRIGAL PHARMACEUTICALS INC
558868105
$102.8M
1.38%
5
TG THERAPEUTICS INC
88322Q108
$100.3M
1.35%
6
INSMED INC
457669307
$99.4M
1.34%
7
SCHOLAR ROCK HOLDING CORP
80706P103
$96.5M
1.30%
8
APOGEE THERAPEUTICS INC
03770N101
$95.5M
1.28%
9
PROTAGONIST THERAPEUTICS INC
74366E102
$92.5M
1.24%
10
SUMMIT THERAPEUTICS INC
86627T108
$92.3M
1.24%
Full holdings, position changes between periods, fund overlap, cross-fund crowding and securities lending detail for XBI are in the ETF X-Ray dashboard.